207_Combined course Presentations

Korean phase II trial

• Cisplatin – Weekly 40 mg/m 2 weekly x 6 cycles – 3-weekly 75 mg/m 2 x 3 cycles

• 104 patients, Stage IIB-IVA

• Results – Compliance (weekly 86%, 3-weekly 93%, p > 0.05) – G3-4 neutropenia (weekly 39%, 3-weekly 23%, p = 0.03 ) – 5-y OS (weekly 67%, 3-weekly 89%, p = 0.03 )

Ryu SY, et al. Int J Radiat Oncol Biol Phys. 2011